Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Stanulla

Showing results (111-120 of 146) with videos related to

Pageof 15
Sort By:
Journal of Pediatric Hematology/Oncology|February 28, 2022
Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic LeukemiaRikke L Nielsen, Benjamin O Wolthers, Marianne Helenius, et al.
EMBO Molecular Medicine|November 4, 2018
PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemiaPaulina Richter-Pechańska, Joachim B Kunz, Beat Bornhauser, et al.
Hemasphere|September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapyGunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2017
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndromeOmer Schwartzman, Angela Maria Savino, Michael Gombert, et al.
Nature Immunology|May 2, 2017
S100-alarmin-induced innate immune programming protects newborn infants from sepsisThomas Ulas, Sabine Pirr, Beate Fehlhaber, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
EMBO Molecular Medicine|August 6, 2020
Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursorsBüşra Erarslan-Uysal, Joachim B Kunz, Tobias Rausch, et al.
Blood Advances|April 10, 2024
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALLGaia Gentile, Teresa Poggio, Antonella Catalano, et al.
Pageof 15

Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Journal of Pediatric Hematology/Oncology|February 28, 2022
Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic LeukemiaRikke L Nielsen, Benjamin O Wolthers, Marianne Helenius, et al.
EMBO Molecular Medicine|November 4, 2018
PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemiaPaulina Richter-Pechańska, Joachim B Kunz, Beat Bornhauser, et al.
Hemasphere|September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapyGunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2017
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndromeOmer Schwartzman, Angela Maria Savino, Michael Gombert, et al.
Nature Immunology|May 2, 2017
S100-alarmin-induced innate immune programming protects newborn infants from sepsisThomas Ulas, Sabine Pirr, Beate Fehlhaber, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
EMBO Molecular Medicine|August 6, 2020
Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursorsBüşra Erarslan-Uysal, Joachim B Kunz, Tobias Rausch, et al.
Blood Advances|April 10, 2024
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALLGaia Gentile, Teresa Poggio, Antonella Catalano, et al.
Pageof 15